PharmaBlock Sciences (Nanjing), Inc. is a leading innovative chemistry products and services provider throughout the pharmaceutical R&D process. Its core businesses include: a catalog of specially designed scaffolds and building blocks; custom synthesis; process development; and manufacturing of key intermediates and APIs.Founded in 2006 in Nanjing, PharmaBlock is committed to helping its worldwide customers maximize the discovery and development efficiency of making next generations of medicines. It has rapidly gained recognition for its outstanding capability in the design, synthesis, and supply of lab scale building blocks. Continuing on that success and to provide a more comprehensive and long-term service to valued customers, the company established BTC Pharmaceutical Co., Ltd. in Nantong, Jiangsu province as its pilot plant site in 2015, and acquired Shandong Diai Biotechnology Co., Ltd. in Dezhou, Shandong province as its manufacturing site in 2016. PharmaBlock has partnered with over 80% of the top 20 pharmaceutical companies, and hundreds of small to medium-sized biotechs around the world. In 2011, the company opened a new facility in the San Francisco Bay area ( Pharmablock USA Inc.), aiming for more efficient and timely services to local customers in the United States and EuropeCurrently Pharmablock has 2600 employees at 6 sites in China and US.

NiRACLE is an innovative Contract Research Organization (CRO), providing Near Infrared (NIR) method development, Process Analytical Technology (PAT), Quality by Design (QbD), and process validation support to the pharmaceutical industry. NiRACLE has pioneered the Supervised Principal Component Analysis (SPCA) technology, a novel multivariate data analysis approach that can be used in NIR-related quantitative analysis (US Patent No. US2011/ 0216313 A1).NiRACLE’s services let the clients build high degree of assurance in their products as well as manufacturing processes through historical data analysis, design of experiments (DOE), and multivariate modeling. NiRACLE’s unique ways of combining DOE with both statistical and chemometric modeling speed up product and process development and lower R&D costs.

In this position I am responsible for company's marketing and sales department, including identify new business opportunities, discover new leads, networking, building client relationship, project management, client communication at routine bases, negotiating business terms with customers/ distributors and suppliers, internal collaboration cross functions to achieve common business goals, managing raw material supply chain and identify new external partners. The effort results AstaTech bulk chemical sale increasing year after year since 2010 in an otherwise overall slow industrial environment.

Keystone Business Park2525 Pearl Buck RoadBristol, PA 19007 cluo@astatechinc.comTel : 215-785-3197 X 313Fax: 215-785-2656

NPE is an energy saving firm focusing on coal fire power plants modification. Promoting world leading combustion technology to improve coal efficiency and air quality.

Early drug discovery focused on selectivity, bioavailability and toxicity profile: Synthesis of novel diarylacetylene piperidinyl amides as Neurokinin 1 receptor modulators. Key role in discovering the compound which advanced into preclinical development.Synthesis of novel 2-aminoquinazolines, 2-aminoquinolines and 2-aminopyridopyrimidines as inhibitors of beta-Site APP Cleaving Enzyme for treating Alzheimer's Disease. Improved potency to single digit nM Ki as well as selectivity and ADME properties. Discover a new synthetic route to prepare the cis-isomer analog of JNJ XXXXX816. Synthesis of first in class Medium Acyl-CoA Synthetase 2 (MACS2) inhibitors for diabetes and obesity. Discovered novel 2a/2b dual and 2b selective inhibitors. Improved solubility and CACO properties to address bioavailability issues.Preparation of novel amino-phenylacetic acids as gama-secretase modulators (GSM) for treating Alzheimer's Disease. Most potent analogs had IC50s below 100 nM. Large scale chiral synthesis of a tetrahydronaphthalene, an inhibitor of beta-amyloid1-42 aggregation. Preparation of novel (arylsulfonamidophenyl) pyrazolamines as Neuropeptide Y5 modulators for the treatment of obesity.

Process development of HIV-1 reverse transcriptase inhibitor(DMP266), later become Sustiva™ (Efavirenz).

Early Drug discovery, 2-adrenergic receptor subtype selective agonists as novel pain killer